Docosahexaenoic acid, or DHA, is a long-chain omega-3 fatty acid that plays a structural role in the brain, retina, and nervous system. Demand for it peaks during pregnancy and infancy. For nutraceutical and pharma brands formulating prenatal or infant nutrition products, algal DHA, sourced directly from microalgae rather than fish, has become the preferred ingredient. This article looks at what the clinical evidence shows about its safety and efficacy, and why it has become the go-to source for maternal and infant supplementation.

Why DHA Matters During Pregnancy and Infancy

The fetus and newborn accumulate DHA rapidly during the third trimester and the first two years of life, a period marked by intense brain and retinal development. Because the body only synthesizes limited amounts of DHA from precursor fats, dietary or supplemental intake is the main way mothers and infants meet this demand.

An expert panel convened by the International Society for the Study of Fatty Acids and Lipids (ISSFAL) recommends that pregnant and lactating women consume an average of at least 200 mg of DHA per day. More recent clinical guidance, including recommendations shared at the American College of Obstetricians and Gynecologists (ACOG) by researchers at the University of Kansas Medical Center, suggests an additional 100 to 200 mg of DHA daily throughout pregnancy, for a total intake of at least 350 to 450 mg per day, with higher levels advised for women with low omega-3 status. Some trials have pushed further. A multicenter U.S. trial found that 1,000 mg of DHA per day was more effective than the standard 200 mg dose at reducing early preterm birth (before 34 weeks), and this higher dose was also linked to fewer maternal and neonatal serious adverse events. Plefa + 3

What the Clinical Evidence Shows

A large systematic review commissioned to update the evidence base on maternal and child omega-3 outcomes screened more than 4,000 studies and analyzed 95 randomized controlled trials along with 48 observational studies. It found that prenatal algal DHA or DHA-enriched fish oil supplementation had a modest positive effect on the length of gestation, and a positive effect on birth weight among healthy, term infants, based on moderate strength of evidence. ScienceDirect

Dedicated trials on algal DHA back this up. The DHANI trial, a randomized, double-blind, placebo-controlled study of 957 pregnant women in India, tested 400 mg per day of microencapsulated algal DHA from mid-pregnancy through delivery and assessed newborn size at birth. A companion analysis from the same cohort extended supplementation through six months postpartum and evaluated infant neurodevelopment at 12 months using a validated developmental assessment scale, the kind of long-horizon data regulators and formulators look for. nihnih

Algal DHA also transfers efficiently into breast milk. A randomized trial in Nanjing, China gave lactating women 200 mg per day of algal-oil DHA for eight weeks and measured breast milk fatty acid composition by gas chromatography. Women in the placebo group saw their breast milk DHA concentrations decline significantly over the same period, which shows how directly maternal supplementation supports the DHA supply an infant gets through nursing. nih

For the most vulnerable infants, DHA has been studied as a targeted clinical intervention. A randomized trial in preterm infants weighing between 1,000 and 1,500 grams tested enteral DHA drawn from algal oil, given from the first feed after birth, to see whether it could help prevent necrotizing enterocolitis, a serious inflammatory gastrointestinal condition in premature newborns. PubMed Central

Safety: Why Regulators and Formulators Trust Algal DHA

Safety data on algal DHA goes well beyond efficacy trials. Formal toxicology and bioequivalence work, including a dietary bioequivalence study in piglets and safety evaluations of DHA-rich oil from Schizochytrium species, has been submitted directly to regulatory bodies. Notably, DSM Nutritional Products filed a GRAS (Generally Recognized as Safe) notice with the FDA specifically for algal DHA oil produced from a new Schizochytrium production strain, for use in both preterm and term infant formula, and the FDA issued a formal response letter accepting that determination. nih

Algal DHA also carries sourcing advantages over fish oil. Because it is cultivated through controlled fermentation rather than harvested from the ocean, it avoids the mercury, PCBs, and other marine contaminants that can build up in fish-derived oils, a meaningful consideration for any brand formulating products for pregnant women and infants. It is also allergen-friendly and suitable for vegetarian and vegan product lines, which broadens the addressable market for prenatal and infant nutrition brands.

What This Means for Formulators

For pharma and nutraceutical brands developing prenatal vitamins, infant formulas, or lactation support products, the evidence base for algal DHA is now strong enough to support confident label claims around gestational length, birth weight, and infant neurodevelopment, provided dosing aligns with published clinical thresholds (roughly 200 to 450 mg per day for general prenatal support, with higher doses reserved for populations with documented low omega-3 status). Combined with a clean contaminant profile and an established regulatory pathway, algal DHA offers a well-supported ingredient story for this category.

Sources

1. Newberry SJ, et al. Omega-3 Fatty Acids and Maternal and Child Health: An Updated Systematic Review. PubMed/AHRQ. https://pubmed.ncbi.nlm.nih.gov/30307735/
2. Growth and tolerance of infants fed formula with a new algal source of docosahexaenoic acid: Double-blind, randomized, controlled trial. ScienceDirect. https://www.sciencedirect.com/science/article/pii/S0952327816300515
3. Prenatal Maternal DHA Supplementation and Newborn Anthropometry in India: Findings from DHANI. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996222/
4. Effect of Maternal DHA Supplementation on Offspring Neurodevelopment at 12 Months in India: A Randomized Controlled Trial. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC7600740/
5. Impact of DHA from Algal Oil on the Breast Milk DHA Levels of Lactating Women: A Randomized Controlled Trial in China. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415549/
6. Efficacy of Docosahexaenoic Acid for the Prevention of Necrotizing Enterocolitis in Preterm Infants: A Randomized Clinical Trial. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922869/
7. Omega-3s. Vegan Health (summarizing ISSFAL 2007 Consensus Statement). https://veganhealth.org/omega-3s-part-2/
8. Highlights from ACOG: DHA guidelines. dsm-firmenich Health, Nutrition & Care. https://www.dsm-firmenich.com/en/businesses/health-nutrition-care/news/talking-nutrition/highlights-from-acog.html
9. Ramiro-Cortijo D, et al. Higher dose docosahexaenoic acid supplementation during pregnancy and early preterm birth: A randomised, double-blind, adaptive-design superiority trial. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257993/

Note: Dosage recommendations vary by health authority and should be confirmed against current regulatory guidance for the target market before use in product labeling or marketing claims.